Competing Interests: Disclosures Drs Lu and Krumholz had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr Jastreboff conducts multicenter trials with Eli Lilly, Novo Nordisk, and Rhythm Pharmaceuticals; serves on scientific advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Eli Lilly, Intellihealth, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Scholar Rock, Structure Therapeutics, Terms Pharmaceutical, WeightWatchers, and Zealand Pharmaceuticals; was the site principal investigator for the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial at Yale University; and receives institutional grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Dr Rodriguez reports consulting relationships with Healthpals, Novartis, Esperion, NovoNordisk (Clinical Events Committee), Movano Health, and Kento Health. In the past three years, Harlan Krumholz received expenses or personal fees from Element Science, Eyedentify, and F-Prime. He is a co-founder of Hugo Health, Refactor Health, and Ensight-AI. He is the co-editor of Journal Watch: Cardiology of the Massachusetts Medical Society and is a section editor of UpToDate. He is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services and through Yale University from Janssen, Johnson & Johnson Consumer, and Pfizer. Dr. Lu received support from the Sentara Research Foundation, the National Heart, Lung, and Blood Institute of the National Institutes of Health (under awards R01HL69954 and R01HL169171), and the Patient-Centered Outcomes Research Institute (under award HM-2022C2-28354). Dr. Khera is an Associate Editor of JAMA. He receives support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775) and the Doris Duke Charitable Foundation (under award 2022060). He also receives research support, through Yale, from Bristol-Myers Squibb and Novo Nordisk. He is a coinventor of U.S. Provisional Patent Applications 63/177,117, 63/428,569, 63/346,610, 63/484,426, and 63/508,315. He is a co-founder of Ensight-AI and Evidence2Health, health platforms to improve cardiovascular diagnosis and evidence-based cardiovascular care. All data used in this study are publicly available at https://www.cdc.gov/nchs/nhanes/index.htm. The other authors report no conflicts.